Form 4 for PRME Prime Medicine, Inc.
Accepted 2022-10-26 00:00:00 ET · period of report 2022-10-24 · accession 0000315066-22-001801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2022-10-26 | 2022-10-24 | PRME | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +8.46M | 99.0K | New | — |
| DMI | 2022-10-26 | 2022-10-24 | PRME | FMR LLC | See Remark 1 | C - Cnv Deriv | — | -8.46M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-24 | C | A | 11,015 | — | 109,982 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 2 | Common | Common Stock | 2022-10-24 | C | A | 4,124,375 | — | 4,124,375 | I F-Prime Capital Partners Life Sciences Fund VI LP | — | — | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 3 | Common | Common Stock | 2022-10-24 | C | A | 423,509 | — | 4,228,589 | I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 4 | Common | Common Stock | 2022-10-24 | C | A | 3,805,080 | — | 3,805,080 | I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 5 | Common | Common Stock | 2022-10-24 | C | A | 98,967 | — | 98,967 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 6 | Derivative | Series B Convertible Preferred Stock | 2022-10-24 | C | D | 423,509 | — | 0 | I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 423,509 Common Stock | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 7 | Derivative | Series A Convertible Preferred Stock | 2022-10-24 | C | D | 4,124,375 | — | 0 | I F-Prime Capital Partners Life Sciences Fund VI LP | — · — to — | 4,124,375 Common Stock | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 8 | Derivative | Series A Convertible Preferred Stock | 2022-10-24 | C | D | 3,805,080 | — | 0 | I Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 3,805,080 Common Stock | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 9 | Derivative | Series B Convertible Preferred Stock | 2022-10-24 | C | D | 11,015 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 11,015 Common Stock | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| 10 | Derivative | Series A Convertible Preferred Stock | 2022-10-24 | C | D | 98,967 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 98,967 Common Stock | (F1) On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |